In a review editorial for the journal Psychotherapy and Psychosomatics, neurobiology researcher Steven Dubovsky from the University at Buffalo argues against the adoption of genetic tests in psychiatry. He calls on colleagues to resist the pressures to “appear scientific”and support industry marketing by critically examining any new genetic findings.
The Milwaukee Journal Sentinel has issued a watchdog report titled “Illness Inflation” that examines how new medical conditions are often the product of industry groups aiming to create a market for expensive new drugs. "There are powerful interests that want the numbers to be inflated," said Allan Horwitz, a professor of sociology at Rutgers University and author of "Creating Mental Illness." "All of these estimates push the numbers upward."
For CounterPunch, Martha Rosenberg and Ronnie Cummins comment on the announcement that Bayer has placed a bid to buy Monsanto. “Bayer and Monsanto both sell controversial toxic agricultural chemicals and GMO seeds,” they write. “But if Bayer’s bid to take over Monsanto goes through, it would mark Monsanto’s first entry into Big Pharma.”
Ed Silverman reports for STAT’s Pharmalot that high-ranking congressmen are accusing the Department of Health and Human Services of deliberately delaying new guidelines on the marketing of drugs off-label, or for unproven uses. In the absence of new guidelines, some worry that court rulings will end up determining policy. Meanwhile, the FDA has expressed concern that marketing claims not backed up by sufficient evidence can lead to public health problems and raise health care costs.
Last week, reports circulated about a system through which drug companies used charitable giving for profit. Now, three drug manufacturers, Gilead Sciences Inc., Biogen Inc. and Jazz Pharmaceuticals Plc, are under federal investigation. For Bloomberg Businessweek’s story on drugmakers and charities, click here.
In Part Two, I discuss strategy and tactics for the Rehumanizing Resistance, including: (1) Traditional, Personal, and Underground Politics; (2) Direct Action and Confrontation: When It Can and Cannot Succeed (3) Organizing: Taking Advantage of the Current Cultural Climate; (4) Alliances and Coalitions; and (5) Film and Media. In Part One, I discussed how the Resistance has been winning scientific battles but losing the war against the expansion of influence of First-Order Psychiatry (which includes American Psychiatric Association and Big Pharma), and how this is due in large part to the First-Order’s effective political tactics and the Resistance’s political naivety.
Everything was not okay, but how could I possibly explain? That I don’t belong here. That I am a phony, a fraud. That I am damaged beyond repair and unsuitable for this work. I felt it happening again: the pressure building in my chest and the tears burning my throat at the prospect of someone discovering my deepest, darkest secret. The precursor to my entire life falling apart.
Psychiatric medications such as antipsychotics and antidepressants account for a huge number of published research studies. This existing research, however, is almost exclusively constrained within a medical model approach, purporting to evaluate medications as treatment for biological brain disorders, and designing studies accordingly. The disease, and how medications presumably affect it, is at the center — with pharmaceutical company financial interests not far behind. That paradigm is starting to change.
A study published in the journal Pediatrics reveals large differences from one pediatrician to the next when it comes to diagnosing and prescribing drugs for ‘ADHD.’ The researchers found that the percentage of children being diagnosed with ‘ADHD’ varied from as high as 16% of patients at some offices to as little as 1% of patients at others. The data also revealed significant but lower variability in the pediatric diagnosis of anxiety and depression.
Mental health campaigner Chrys Muirhead’s blog features video from the All-Party Parliamentary Group for Prescribed Drug Dependence event on 11 May 2016 at Westminster. “Robert Whitaker, the Pulitzer-shortlisted science journalist and author, presented global prescribing and disability data, as well as research which shows how long-term use of psychiatric drugs, including antidepressants, can lead to worse outcomes for patients.”
Copyright © 2016 Mad in America Foundation.